1. Scrip
  2. >>Drug Pricing

Amgen Does Not Expect Big Enbrel Price Impact From US Humira Biosimilar Launches

Q3 Revenue Down 1% But Beat Analyst Consensus

 
• By Mandy Jackson

Amgen will be first to launch a Humira biosimilar in the US with its Amgevita, but it and other adalimumab copies may add pressure to the company’s already declining top-seller Enbrel.

Sign from Amgen building in Switzerland
Amgen's $6.65bn in Q3 revenue beat consensus expectations of $6.57bn • Source: Shutterstock

Amgen, Inc. does not expect the launch of biosimilars for AbbVie Inc.’s TNF inhibitor Humira (adalimumab) to cause its own anti-TNF antibody and top-selling product Enbrel (etanercept) to experience net price declines in 2023 that are any more dramatic than the price cuts already implemented in 2022 to keep the product on payers’ formularies. And as the first company slated to launch a Humira biosimilar in the US, Amgen has a front seat to the competitive dynamics next year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Mounjaro In India: Price Differential, Window Of Opportunity

 
• By Anju Ghangurde

Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?

Stelara Biosimilars Storm US Market With 85% Discounts Ahead Of Price Drop In Medicare

 
• By Cathy Kelly

The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.

Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval

 
• By Jessica Merrill

Amvuttra will target a substantially larger patient population with a new indication, but it is third to market behind Pfizer’s Vyndaqel and Bridge Bio’s Attruby and will cost more.

More from Scrip

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

 
• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

 
• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.

Will Irish Eyes Still Be Smiling When Trump Tariffs Hits Pharma?

 
• By Kevin Grogan

The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.